Pharmacokinetics, Efficacy, and Safety of a SARS-CoV-2 Antibody Treatment in Pediatric Participants: An Open-Label Addendum of a Placebo-Controlled, Randomized Phase 2/3 Trial

ConclusionWBD in pediatric participants achieved similar drug exposures compared to adult participants that received the authorized BAM  + ETE dose. The pediatric efficacy and safety data were consistent with adults receiving mAbs for COVID-19.Trial Registration NumberNCT04427501.
Source: Infectious Diseases and Therapy - Category: Infectious Diseases Source Type: research